Browsing Tag
ARVO 2026
1 post
MingMed Biotechnology’s oral QA102 Phase II data puts intermediate dry AMD in the spotlight
Dry AMD has injection options late, but few answers earlier. MingMed’s QA102 asks whether oral therapy can change that risk window.